Exercise PerformanceNCT06066606
U-LABA/ICS Effects on Exercise Performance, Vilanterol
A study testing Vilanterol and Fluticasone Furoate (low dose) and Vilanterol and Fluticasone Furoate (high dose) in people with Exercise Performance, run by Morten Hostrup, PhD at 1 site in Denmark.
Trial summary
The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist vilanterol + fluticasone furoate Read more about this study
- Who is it for?
- Ages 18 to 39 yearsHealthy volunteers can take part
- Conditions the study is for
- Exercise Performance
- What is being tested?
- Vilanterol and Fluticasone Furoate (low dose) and Vilanterol and Fluticasone Furoate (high dose)
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 30 participants
- Where
- 1 siteDenmark
- Study dates
- 3 Oct 2023to 1 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 39 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age 18-39
- Physically active > 5 h weekly
- Maximal oxygen consumption classified as high or very high
Who cannot join
- Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist/corticosteroid
- ECG abnormality
- ACQ score > 1.5
- Severe bronchial hyperreactivity as determined by mannitol test
- FEV1/FVC ratio < 0.7 determined with spirometry
- Chronic illness determined to be a potential risk for participant during study
Show all 10Show fewer
- In chronic treatment with medication that may interfere with study results
- Pregnancy
- Smoker
- Blood donation during the past 3 months
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Denmark1 site, 1 recruiting
- Recruiting
August Krogh Building
Copenhagen, DK, 2100
Morten Hostrup, PhD
About this study
Official title: Physiological Response to U-LABA/ICS With Emphasis on Exercise Performance, Vilanterol
The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist vilanterol + fluticasone furoate
- Conditions
- Exercise Performance
- Being tested
- Vilanterol and Fluticasone Furoate (low dose), Vilanterol and Fluticasone Furoate (high dose), Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Vilanterol and Fluticasone Furoate (low dose)Drug
Participants are administered 25 µg of vilanterol + fluticasone furoate
Vilanterol and Fluticasone Furoate (high dose)Drug
Participants are administered 100 µg of vilanterol + fluticasone furoate
PlaceboDrug
Participants are administered placebo
| Study group | Role | What they receive |
|---|---|---|
| Vilanterol + fluticasone furoate | Experimental | Participants are administered Vilanterol + fluticasone furoate from an inhaler device testing Receives: Drug: Vilanterol and Fluticasone Furoate (low dose); Drug: Vilanterol and Fluticasone Furoate (high dose) |
| Placebo | Placebo comparator | Participants are administered placebo from an inhaler device testing Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Power output during sprint testing
Power output measured in Watts during a sprint on a bike ergometer
Measured: Through study completion, an average of 3 weeks
Secondary outcomes (1)
Power output during time trial
Mean power output measured in Watts during a time trial on a bike ergometer
Measured: Through study completion, an average of 3 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Oct 2023
- Study start3 Oct 2023
- Primary completion15 Jul 2026 (estimated)
- Study completion1 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Exercise PerformanceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Morten Hostrup, PhD
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Morten Hostrup, PhD, University of Copenhagen
- Investigators
- Morten Hostrup, PhD, Principal investigator, University of Copenhagen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06066606
- Sponsor's protocol ID
- VIL
- Status last verified
- Apr 2025
- First submitted
- 20 Sep 2023
- Last updated
- 10 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 10 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Physiological Response to U-LABA/ICS With Emphasis on Exercise Performance, Vilanterol
- ClinicalTrials.gov ID
- NCT06066606
- Acronym / sponsor ID
- VIL
- Conditions
- Exercise Performance
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Morten Hostrup, PhDUniversity, hospital or other
- Study start
- 3 Oct 2023 (actual)
- Primary completion
- 15 Jul 2026 (estimated)
- Study completion
- 1 Dec 2026 (estimated)
- First posted
- 4 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist vilanterol + fluticasone furoate
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Vilanterol + fluticasone furoate | Experimental | Drug: Vilanterol and Fluticasone Furoate (low dose), Drug: Vilanterol and Fluticasone Furoate (high dose)Participants are administered Vilanterol + fluticasone furoate from an inhaler device testing |
| Placebo | Placebo comparator | Drug: PlaceboParticipants are administered placebo from an inhaler device testing |
Who may qualify
- Ages
- 18 to 39 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Age 18-39
- Physically active > 5 h weekly
- Maximal oxygen consumption classified as high or very high
Key exclusion criteria (10 listed)
- Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist/corticosteroid
- ECG abnormality
- ACQ score > 1.5
- Severe bronchial hyperreactivity as determined by mannitol test
- FEV1/FVC ratio < 0.7 determined with spirometry
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Vilanterol and Fluticasone Furoate (low dose)Participants are administered 25 µg of vilanterol + fluticasone furoate | Drug | Vilanterol + fluticasone furoate |
| Vilanterol and Fluticasone Furoate (high dose)Participants are administered 100 µg of vilanterol + fluticasone furoate | Drug | Vilanterol + fluticasone furoate |
| PlaceboParticipants are administered placebo | Drug | Placebo |
Primary outcome
Power output during sprint testing
Time frame: Through study completion, an average of 3 weeks
Power output measured in Watts during a sprint on a bike ergometer
1 secondary outcome
Power output during time trial
Time frame: Through study completion, an average of 3 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Apr 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Exercise Performance
Not yet recruiting
Dual-Task Core Stabilization Training in Chronic Nonspecific Low Back Pain
Chronic Nonspecific Low Back Pain
Not yet recruiting
Comparative Effects of Exercises on Pain, Cervical Proprioception, Neck Disability and Visual Performance in Patients With Computer Vision Syndrome.
Computer Vision Syndrome
Recruiting
The Effects of Vestibulo-Ocular Reflex Exercises Added to Postural Stabilization Training in Chronic Ankle Instability
Ankle Sprains, Ankle Sprain Strain
Not yet recruiting
Effects of Different Amounts of Plyometric Exercise Without Jumping in Physically Inactive Older Adults
Sedentary Behavior / Physical Inactivity, Aging
Recruiting
Community-Based Exercise and Nutrition Training and Education Program for Cancer Survivors
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Morten Hostrup, PhD principal investigator
University of Copenhagen
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Vilanterol and Fluticasone Furoate (low dose) and Vilanterol and Fluticasone Furoate (high dose) in people with Exercise Performance, run by Morten Hostrup, PhD at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Morten Hostrup, PhD (+4535321595, mhostrup@nexs.ku.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Power output during sprint testing (time frame: Through study completion, an average of 3 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Apr 2025.